Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Jun '17
Revenue
237.26 28.70 7.38 0.11 0.89 4.05 9.86 4.16 5.84 8.90
Revenue Growth
726.68% 288.94% 6,796.26% (88.00%) (77.95%) (58.97%) 137.12% (28.77%) (34.39%) (4.30%)
Gross Profit
237.26 28.70 7.38 0.11 0.89 4.05 9.86 4.16 5.84 8.90
Operating Income
18.07 (66.29) (83.35) (114.59) (72.75) (30.17) (15.78) (21.76) (10.01) (27.50)
EBT
16.80 (66.69) (82.20) (107.69) (70.36) (31.98) (18.15) (17.90) (9.58) (29.10)
Income after Tax
16.33 (66.95) (82.46) (107.76) (70.47) (32.22) (18.64) (18.01) (9.58) (29.40)
Net Income Common
16.33 (66.95) (82.46) (107.76) (70.47) (32.22) (18.64) (18.35) (12.46) (29.40)
EPS (Diluted)
0.07 (0.33) (0.57) (0.84) (0.58) (0.36) (0.86) (2.90) (8.36) (8.37)
Shares (Diluted, Weighted)
230.35 202.14 144.82 127.68 121.45 88.30 21.57 6.32 0.14 3.51
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBIT Margin
7.62% (230.99%) (1,129.52%) (107,090.65%) (8,156.05%) (745.67%) (160.06%) (523.11%) (171.52%) (308.99%)
Net Profit Margin
6.88% (233.27%) (1,117.56%) (100,708.41%) (7,900.22%) (796.34%) (189.06%) (441.12%) (213.39%) (330.34%)
Free Cash Flow Margin
3.19% (157.90%) (978.51%) (97,551.40%) (7,285.76%) (617.15%) (141.35%) (366.79%) (172.75%) (337.08%)
EBITDA
26.38 (58.20) (75.38) (108.94) (68.46) (27.46) (12.19) (18.53) (9.47) (27.40)
EBIT
18.07 (66.29) (83.35) (114.59) (72.75) (30.17) (15.78) (21.76) (10.01) (27.50)

Show all line items

In millions of $ except per-share values · columns are period end dates